These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20307035)

  • 41. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections.
    Coscas F; Querques G; Forte R; Terrada C; Coscas G; Souied EH
    Retina; 2012 Jun; 32(6):1069-76. PubMed ID: 22466476
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration.
    Tao Y; Jonas JB
    J Ocul Pharmacol Ther; 2010 Apr; 26(2):207-12. PubMed ID: 20415625
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.
    Krebs I; Schmetterer L; Boltz A; Told R; Vécsei-Marlovits V; Egger S; Schönherr U; Haas A; Ansari-Shahrezaei S; Binder S;
    Br J Ophthalmol; 2013 Mar; 97(3):266-71. PubMed ID: 23292928
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bevacizumab and ranibizumab for neovascular age-related macular degeneration: a treatment approach based on individual patient needs.
    Bellerive C; Cinq-Mars B; Lalonde G; Malenfant M; Tourville E; Tardif Y; Giasson M; Hébert M
    Can J Ophthalmol; 2012 Apr; 47(2):165-9. PubMed ID: 22560423
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy.
    Horsley MB; Mandava N; Maycotte MA; Kahook MY
    Am J Ophthalmol; 2010 Oct; 150(4):558-561.e1. PubMed ID: 20643396
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Retinal pigment epithelium tear after intravitreal bevacizumab for exudative age-related macular degeneration.
    Spandau UH; Jonas JB
    Am J Ophthalmol; 2006 Dec; 142(6):1068-70. PubMed ID: 17157597
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Retinal pigment epithelium tears in age-related macular degeneration treated with antiangiogenic drugs: a controlled study with long follow-up.
    Coco RM; Sanabria MR; Hernandez AG; Fernández Muñoz M
    Ophthalmologica; 2012; 228(2):78-83. PubMed ID: 22710369
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
    Melamud A; Stinnett S; Fekrat S
    Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
    [TBL] [Abstract][Full Text] [Related]  

  • 50. POOR LONG-TERM OUTCOME OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN NONPROLIFERATIVE MACULAR TELANGIECTASIA TYPE 2.
    Kupitz EH; Heeren TF; Holz FG; Charbel Issa P
    Retina; 2015 Dec; 35(12):2619-26. PubMed ID: 26340529
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.
    Subramanian ML; Ness S; Abedi G; Ahmed E; Daly M; Feinberg E; Bhatia S; Patel P; Nguyen M; Houranieh A
    Am J Ophthalmol; 2009 Dec; 148(6):875-82.e1. PubMed ID: 19800611
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type.
    Jonas JB; Libondi T; Ihloff AK; Harder B; Kreissig I; Schlichtenbrede F; Sauder G; Spandau UH
    Acta Ophthalmol Scand; 2007 Aug; 85(5):563-5. PubMed ID: 17324219
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration.
    Stepien KE; Rosenfeld PJ; Puliafito CA; Feuer W; Shi W; Al-Attar L; Dubovy SR; Murray TG; Davis JL; Lee WH; Schwartz SG; Smiddy WE; Berrocal AM; Flynn HW
    Retina; 2009 Sep; 29(8):1067-73. PubMed ID: 19696701
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-VEGF therapy in symptomatic peripheral exudative hemorrhagic chorioretinopathy (PEHCR) involving the macula.
    Seibel I; Hager A; Duncker T; Riechardt AI; Nürnberg D; Klein JP; Rehak M; Joussen AM
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):653-9. PubMed ID: 26148802
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of choroidal neovascularization using intravitreal bevacizumab.
    Pedersen R; Soliman W; Lund-Andersen H; Larsen M
    Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results.
    Carneiro AM; Falcão MS; Brandão EM; Falcão-Reis FM
    Retina; 2010 Jan; 30(1):85-92. PubMed ID: 20010320
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks.
    Lushchyk T; Amarakoon S; Martinez-Ciriano JP; van den Born LI; Baarsma GS; Missotten T
    Acta Ophthalmol; 2013 Sep; 91(6):e456-61. PubMed ID: 23773796
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Functional and anatomic efficacy of a conversion to aflibercept in eyes with age-related macular degeneration after long-term ranibizumab treatment.
    Gerding H
    Klin Monbl Augenheilkd; 2015 Apr; 232(4):560-3. PubMed ID: 25902122
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outcome of bevacizumab (Avastin) injection in patients with age-related macular degeneration and low visual acuity.
    Ehrlich R; Weinberger D; Priel E; Axer-Siegel R
    Retina; 2008 Oct; 28(9):1302-7. PubMed ID: 18664935
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of monthly and fortnightly anti-VEGF treatments for age-related macular degeneration.
    Nunes RP; Hirai FE; Barroso LF; Badaró E; Novais E; Rodrigues EB; Maia M; Magalhães O; Farah ME
    Arq Bras Oftalmol; 2019; 82(3):225-232. PubMed ID: 30810619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.